A detailed history of Rhumbline Advisers transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 39,656 shares of ATNM stock, worth $76,536. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,656
Previous 32,131 23.42%
Holding current value
$76,536
Previous $251,000 16.73%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$6.56 - $9.89 $49,364 - $74,422
7,525 Added 23.42%
39,656 $293,000
Q1 2024

May 09, 2024

BUY
$5.0 - $9.2 $2,415 - $4,443
483 Added 1.53%
32,131 $251,000
Q4 2023

Feb 08, 2024

BUY
$4.02 - $6.08 $3,545 - $5,362
882 Added 2.87%
31,648 $160,000
Q3 2023

Nov 09, 2023

BUY
$5.91 - $7.37 $6,595 - $8,224
1,116 Added 3.76%
30,766 $182,000
Q2 2023

Aug 08, 2023

BUY
$7.15 - $9.39 $211,997 - $278,413
29,650 New
29,650 $220,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $48.6M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.